



**SPEECH INFORMATION (For Conference Program Book)**

Topic	Translating Psychobiotics from Laboratory Research to Global Markets
Abstract	<p>Psychobiotics represent a rapidly emerging field at the intersection of microbiome science and mental health, yet translating laboratory findings into globally scalable products remains a significant challenge. This talk uses <i>Lactobacillus plantarum</i> PS128 as a case study to examine the scientific, regulatory, and market barriers encountered in the commercialization of psychobiotic interventions.</p> <p>Drawing on over a decade of preclinical and clinical research, PS128 has been investigated across multiple neuropsychiatric and neurological indications, including stress-related disorders, sleep disturbance, autism spectrum disorder, and Parkinson's disease. Despite growing clinical evidence, successful market translation has required more than efficacy alone, demanding careful alignment between mechanism-driven research, regulatory expectations across regions, and culturally differentiated consumer health markets.</p> <p>The presentation will explore how clinical trial design, biomarker selection, and indication positioning influence regulatory pathways and commercial viability. It will further discuss lessons learned from expanding PS128-based products into Asia, Europe, and North America, highlighting strategic decisions in formulation, branding, and evidence communication. By bridging scientific rigor with real-world constraints, this talk aims to provide a practical framework for translating psychobiotic research into globally relevant mental health solutions.</p>

